Class Action Article

  • File A Talcum Powder Lawsuit: Talcum Powder Ovarian Cancer Lawsuits Talcum Powder Fallopian Tube Cancer Lawsuits Baby  Powder Ovarian Cancer Lawsuits Filed If you or a loved one used talcum powder products and were diagnosed with ovarian cancer, or fallopian tube can...

Class Action News

Drug Class Actions

  • Taxotere Lawyers for Permanent Hair Loss: Taxotere Baldness Lawyers For  Permanent Hair Loss Lawsuits Have you received Taxotere for breast cancer? Taxotere can result in hair loss or baldness  that is permanent. Taxotere  is a chemotherapy drug used for the treatment of breas...

Medical Device Lawsuits

  • Get A Hernia Mesh Lawyer | Hernia Mesh Lawsuits Filed: The hernia mesh lawyers of Class Action Lawyer Network are filing hernia mesh lawsuits for victims of a failed hernia mesh. We have Ethicon, Bard and Cook hernia mesh lawyers. Hernia Mesh Lawsuits Filed  For: Ethicon: Physiomesh Pro...

Posts Tagged ‘bladder cancer’

Actos Lawyers, Actos News, Actos Bladder Cancer Victims

Written by Class Action Lawyer on . Posted in Louisiana Multidistrict Litigation Lawyers

Actos has warnings for bladder cancer. Actos cases have been consolidated and Actos Lawyers are accepting clients.

The judge overseeing lawsuits alleging Takeda Pharmaceutical Co. (4502)’s Actos diabetes medicine causes cancer appointed 19 plaintiffs’ lawyers to manage litigation involving U.S. claims.

Takeda, Asia’s biggest drugmaker, may face as many as 10,000 claims that Actos causes bladder cancer after U.S. regulators found last year the drug was linked to the disease. Federal lawsuits against the drugmaker were consolidated before U.S. District Judge Rebecca Doherty in Lafayette, Louisiana, in December. The first hearing on the cases is set for March 22, according to court filings.

“The court has determined to effect the selection of lead counsel, liaison counsel and plaintiffs’ executive and steering committees before the March 22nd-23rd status conference,” Doherty said in a March 12 note posted on the court’s website.

The lawsuits claim patients who use Actos, a prescription drug approved to treat type 2 diabetes, face increased risks of developing bladder cancer. The plaintiffs also claim that Takeda and co-defendant Eli Lilly & Co., based in Indianapolis, withheld information about the risk and failed to provide adequate warnings.

Takeda pulled Actos, its top-selling drug, off the market in Germany and France last year after it was linked to an increased cancer risk. The medication had sales of 387.9 billion yen ($4.8 billion) last fiscal year, 27 percent of the Osaka, Japan-based company’s revenue.
Lead Counsel

“Given that litigation is pending, we can’t comment,” Jocelyn Gerst, a U.S.-based spokeswoman for Takeda, said in a telephone interview about the selection of the plaintiffs’ group.

Doherty named attorneys Richard Arsenault and Paul Pennock as lead plaintiffs’ counsel in the case and also appointed them to the executive committee, along with lawyers Mark Robinson and Hunter Shkolnik.

Arsenault, a products-liability lawyer based in Alexandria, Louisiana, served as one of the lead lawyers in consolidated cases filed against Merck & Co. (MRK) over its Vioxx painkiller that resulted in a $4.85 billion settlement in November 2007.

Pennock, a New York-based attorney, was one of the lawyers leading the consolidated suits against AstraZeneca Plc (AZN) over its Seroquel antipsychotic drug. The London-based drugmaker agreed last year to pay a total of about $350 million to resolve patients’ claims that the drug caused diabetes.
Steering Committee

The Los Angeles-based Robinson, who has won multimillion- dollar jury awards against carmakers such as Ford Motor Co., is a co-lead counsel in sudden-acceleration lawsuits against Toyota Motor Corp. (7203)

Shkolnik, based in New York City, served as a member of the plaintiffs’ steering committee in lawsuits against Medtronic Inc. (MDT) over flawed heart defibrillators. The cases later settled for more than $114 million.

Other lawyers named to the plaintiffs’ steering committee in the Actos cases include Mark Lanier, a Texas-based lawyer who won the first jury award against Whitehouse Station, New Jersey- based Merck in the Vioxx litigation, and Chris Seeger, a New Jersey-based attorney who also won a verdict against Merck on behalf of Vioxx users.

The judge also named Andy Birchfield, an Alabama-based lawyer who helped negotiate the $4.85 billion Vioxx settlement, and Vance Andrus, a Lafayette-based lawyer who was one of the lead counsels in cases against GlaxoSmithKline Plc (GS) over its Avandia diabetes drug. The London-based drugmaker has agreed to pay more than $700 million to resolve claims that Avandia caused heart attacks and strokes in users.

The lawsuits are consolidated in In Re: Actos Products Liability Litigation, 11-2299, U.S. District Court, Western District of Louisiana (Lafayette).

Lawyers Still Accepting Actos Cases, Actos Causing Bladder Cancer

Written by Class Action Lawyer on . Posted in Class MDL Class Action News

Lawyers Still Accepting Actos Cases as First Hearing Set to Begin. If you or a loved one has been diagnosed with bladder cancer from Actos contact us for an Actos lawyer today.

10,000 Actos lawsuits are expected to be filed
Orlando, FL (PRWEB) February 21, 2012
A federal judge tasked with overseeing the litigation over whether a popular diabetes drug caused bladder cancer in hundreds of patients is moving quickly to expedite the legal process for both sides.
While those who have already filed an Actos lawsuit are one step closer to having their day in court, lawyers are still helping those who are just coming forward with side effects.
On Monday, February 13, U.S. District Judge Rebecca Doherty issued an order scheduling a pretrial status conference in the Actos litigation for March 22, 2012. The hearing will give representatives of the drug manufacturer and those of patients alleging bladder cancer from the drug a chance to discuss trial preparation and whether any progress has been made in reaching a settlement.
After the hearing, Judge Doherty will also appoint lead counsel in the consolidated cases from her bench in Lafayette, Louisiana.
Doherty was originally assigned to dozens of the lawsuits in Multi-District Litigation following an order by the U.S. Judicial Panel on Multidistrict Litigation in December. She now presides over approximately 150 cases and lawyers expect thousands more may be filed before litigation is complete. The pending case is In Re: Actos Products Liability Litigation, MDL 2299, U.S. District Court, Western District of Louisiana (Lafayette).
Lawyers with the Actos Resource Center have responded to hundreds of inquiries from those who have taken Actos and expect many more will come forward due to the popularity of the drug.
On June 15, 2011, the FDA issued a warning that taking Actos for longer than one year could heighten the risk of bladder cancer. Approved by the FDA in 1999, Actos had become one of the most popular diabetes drugs in the world after rival Avandia was linked to heart problems.
The warning came after a study of 155,000 patients over four years by the French Medicines Agency showed taking Actos could increase the occurrence of bladder cancer by up to 40%.
Authorities in France and Germany quickly banned sales of the drug. However, it remains on the market in the United States.
Now, according to a Bloomberg article published December 1, 2011, drug makers Takeda Pharmaceuticals and Eli Lilly could face as many as 10,000 lawsuits from those stricken with bladder cancer after taking Actos.
On Tuesday, Takeda released a statement saying "Takeda is confident in the therapeutic benefits of Actos and its importance as a treatment for type 2 diabetes. As a science and evidence-based company, Takeda firmly stands behind the substantial data available confirming the positive risk/benefit profile of Actos, which includes twelve years of clinical and patient experience with the product."
For more information on the side effects, FDA warnings and litigation associated with Actos, visit

Class Action Lawyer Netrwork Actos Lawyers are accepting cases for bladder cancer form Actos. These are part of an Actos Multi District litigation.

Type 2 Diabetics, Actos and Bladder Cancer

Written by Class Action Lawyer on . Posted in Drug Lawsuits

  Type II  Diabetics are showing side effects from actos. There have been significant reports showing the relationship between actos and bladder cancer. It is alleged that the manufacturer should have been aware and warned Type 2 Diabetics about actos side effects.
      ACTOS is a prescription drug used with diet and exercise to improve blood sugar (glucose) control in adults with type ii diabetes. ACTOS is not for patients with type 1 "juvenile" diabetes or diabetic ketoacidosis. It is impossible for a patient to assess the safety of a drug before taking it.. Helpless and vulnerable patients rely on others such as drug manufacturers,physicians and pharmacists to help make the right decision regarding the medications they take. While many drugs do what they are intended to do and help relieve symptoms improve quality of life, some drugs are defective and dangerous. Patients trust the physicians and when a "good" drug turns bad they do not know where to turn. Some groups have a higher risk for developing type 2 diabetes than others. Type 2 diabetes is more common in the aged population.Caregivers must step up to assist their older patients who are affected by actos Being the primary caregiver for a person who has diabetes can take an emotional toll. A diabetes caregiver may be the one taking ownership of his or her loved one's diabetes if the person with diabetes doesn't or can't. There may be feelings of guilt,that is why they must step up on behalf of their patients and loved ones to protect them. Actos has been shown to have serious side effects including heart problems and bladder cancer. EHealthMe conducted a study on August 17, 2011 regarding the side effects of taking Actos and the bladder cancer risk. According to the report, 22,512 reported side effects when taking Actos and 0.22% have bladder cancer. The largest concentration (approx. 43%) were using Actos between 2-5 years before having Bladder Cancer with the next largest concentration (approx. 29%) used Actos between 1-6 months. Older populations and many minority groups  are effected by these new findings.

TYpe II Diabetes Information

          Type 2 diabetes, also known as adult-onset or noninsulin-dependent diabetes, is a chronic condition that affects the way your body metabolizes sugar (glucose), your body's main source of fuel.Insulin is a hormone that regulates the movement of sugar into your cells.With type 2 diabetes, your body either resists the positive effects of insulin or doesn't produce enough insulin to maintain a normal glucose level. Untreated, type 2 diabetes can be life-threatening. Complications of Diabetes Diabetes can lead to high blood sugar levels, a condition called hyperglycemia. Over a long period of time, hyperglycemia damages the retina of the eye, the kidneys, the nerves, and the blood vessels.Damage to the retina from diabetes (diabetic retinopathy) is a leading cause of blindness.Damage to the kidneys from diabetes (diabetic nephropathy) is a leading cause of kidney failure. Damage to the retina from diabetes (diabetic retinopathy) is a leading cause of blindness.Damage to the nerves from diabetes (diabetic neuropathy) is a leading cause of foot wounds and ulcers, which frequently lead to foot and leg amputations.Damage to the nerves in the autonomic nervous system can lead to paralysis of the stomach (gastroparesis), chronic diarrhea, and an inability to control heart rate and blood pressure during postural changes
Ads by Google
           Damage to the nerves in the autonomic nervous system can lead to paralysis of the stomach (gastroparesis), chronic diarrhea, and an inability to control heart rate and blood pressure during postural changes.Diabetes accelerates atherosclerosis, (the formation of fatty plaques inside the arteries), which can lead to blockages or a clot (thrombus). Such changes can then lead to heart attack, stroke, and decreased circulation in the arms and legs. Damage to the nerves from diabetes (diabetic neuropathy) is a leading cause of foot wounds and ulcers, which frequently lead to foot and leg amputations(peripheral vascular disease).Damage to the nerves from diabetes (diabetic neuropathy) is a leading cause of foot wounds and ulcers, which frequently lead to foot and leg amputations.Damage to the nerves in the autonomic nervous system can lead to paralysis of the stomach (gastroparesis), chronic diarrhea, and an inability to control heart rate and blood pressure during postural changes. Diabetes accelerates atherosclerosis, (the formation of fatty plaques inside the arteries), which can lead to blockages or a clot (thrombus). Such changes can then lead to heart attack, stroke, and decreased circulation in the arms and legs (peripheral vascular disease).As of June 10, 2011 doctors in France and Germany have been instructed not to proscribe the drug Actos to their  Type II Diabetic patients and the drug Actos has actually been removed from pharmacy shelves. The reason for these actions is because recent studies have shown that an patients who use the drug Actos to treat their Type II Diabetes by using Actos are more likely to contract bladder cancer.
               What makes this fact more difficult to accept is that it appears that the incidence of Bladder Cancer in Type II Diabetics using the drug Actos, was known to the drug manufacturer Takeda, Inc. in the clinical trials However, even though, Takeda, Inc. apparently knew that the drug Actos would cause bladder cancer, it still marketed and sold 2.3 million prescriptions for the drug Actos in the United States in one year alone. 2010. The active ingredient in Actos, Pioglitazone, is also used in ActoPlus met, ActoPlus met XR and Duetac to treat Type 2 Diabetes.
              On June 15, 2011, the FDA issued an urgent health warning to users and prescribers of the drug Actos acknowledging the recent statistical data that shows up to a 40% increase in risk for bladder cancer in users of Actos. The studies further show that the risk of bladder cancer increases with higher dosages and longer courses of treatment with Actos.In one study involving more than 193,000 patients with diabetes, patients taking Actos were on the drug for an average of two years, the FDA said. "Compared to never being exposed to pioglitazone, a duration of pioglitazone therapy longer than 12 months was associated with a 40 percent increase in risk [for bladder cancer]," the agency said. A French study examined cancer rates in some 155,000 people taking Actos in France from 2006 to 2009 and 1.3 million other diabetics who were not receiving the drug. The study found about a 22 percent higher risk of bladder cancer in those taking Actos compared with diabetics taking other drugs. The bladder cancer risk was highest in those receiving a cumulative Actos dosage of 28,000 mg or more during the study period.Patients taking the diabetes drug Actos for more than a year may have an increased risk of bladder cancer, according to an FDA interim review of an ongoing epidemiological study.After the health warning was issued the FDA will now require that these recent findings and risks be included in warnings attached to the drug packaging and future marketing materials. The FDA is also going to continue monitor the data being released by various.  So  far, Actos remains available to consumers in the United States despite these risks

Class Action Lawyer Network  Actos team is ready to help you. If you or a loved one has been injured by actos call now and speak to our medical MSW. As a caregiver for someone who may be a victim of Actos you should call us immediately and get the facts.

GlaxoSmithKline Plc agreed to pay $3 billion to resolve U.S.

Written by Class Action Lawyer on . Posted in Class MDL Class Action News

By Phil Serafino and Makiko Kitamura, Published: November 3

Nov. 3 (Bloomberg) — GlaxoSmithKline Plc agreed to pay $3 billion to resolve U.S. criminal and civil investigations into whether the U.K. company marketed drugs for unapproved uses and other matters, its biggest legal settlement.

Negotiations over the terms will be completed next year, the London-based company said in a statement today. The cost is covered by existing legal provisions and will be paid from the company’s cash resources, Glaxo said.

The potential settlement brings Glaxo closer to putting years of legal probes behind it. The company set aside 2.2 billion pounds ($3.5 billion) in the fourth quarter last year in anticipation of reaching an agreement on the cases. Glaxo said it will have about 1 billion pounds of its 2.9 billion pounds in total legal provisions remaining after today’s settlement is completed, and it hasn’t decided what to do with the money.

“This news essentially draws a line under a 10-year legal saga,” Gbola Amusa, an analyst at UBS AG in London who recommends buying Glaxo shares, said in an e-mail. “This removes significant uncertainty on ongoing legal issues.”

Glaxo rose 1.7 percent to close at 1,378 pence in London.

Pfizer Settlement

The Glaxo settlement would trump the $2.3 billion Pfizer Inc. paid in 2009 over the marketing of its Bextra painkiller and other drugs and the $1.4 billion Eli Lilly & Co. paid the same year over sales of its Zyprexa anti-psychotic medicine. The Bextra accord had been the largest pharmaceutical marketing settlement in U.S. history.

Abbott Laboratories agreed to pay at least $1.3 billion to settle claims by the U.S. government and 24 states alleging the company illegally marketed its Depakote epilepsy drug, people familiar with the accords said last month.

“Litigation is an ever-present business risk in the pharmaceuticals industry,” Mark Purcell, a Barclays Capital analyst, wrote in a note to investors today.

The proposed $3 billion settlement is “manageable,” Fitch Ratings said today in a statement. “It should help remove some uncertainty about the group’s finances without putting significant pressure on its ’A+’ credit rating.”

Federal prosecutors began an investigation in Colorado in 2004, later taken over by the U.S. attorney in Massachusetts, into whether Glaxo promoted drugs for unapproved uses, and into ways Glaxo potentially influenced doctors. The probe concerns nine of the company’s best-selling products from 1997 to 2004, including the Advair lung treatment, Glaxo said in its annual report.

Medicaid Rebates

Today’s settlement also covers a U.S. Justice Department probe of Glaxo and a Medicaid rebate program, and a Justice Department investigation into the development and marketing of the Avandia diabetes drug, the company said.

Drugmakers are required to give rebates to Medicaid, the government health insurance program for the poor. The investigation examined how Glaxo reported prices charged to other payers, which are used in calculating the Medicaid rebates.

Regulators said last year that Avandia would be withdrawn from the market in Europe and sales would be limited in the U.S. because of an increased risk of heart attacks.

“This is a significant step toward resolving difficult, longstanding matters which do not reflect the company that we are today,” Chief Executive Officer Andrew Witty said in the statement. “In recent years, we have fundamentally changed our procedures for compliance, marketing and selling in the U.S. to ensure that we operate with high standards of integrity.”

Compensation Changes

Earlier this year, Glaxo changed incentive compensation programs for U.S. sales representatives. The company has eliminated the link between sales goals and bonuses, which are now based on selling competency, customer evaluations and overall performance of the representative’s business unit.

Glaxo still faces probes involving the United Nations oil- for-food program, and HIV product sales and marketing in the U.S., JPMorgan Chase & Co. analysts wrote in a note to investors today.

The company agreed to pay more than $250 million to resolve about 5,500 claims related to Avandia to avoid the first trials over claims it can kill users, two people familiar with the accords said in February. Glaxo declined to comment on those figures today.

‘Speed Bumps’

“These settlements are just speed bumps to drug companies, a small blip in their global revenue,” said Kevin Outterson, a professor of health law at Boston University and editor-in-chief of the Journal of Law, Medicine & Ethics. “This may also be the last U.S. settlement on off-label promotion, as the companies are now using the First Amendment as a shield for off-label promotion.”

The legal provision, announced in January, led to a loss for Glaxo in the fourth quarter of 2010. Less than three weeks after the provision was disclosed, the company said it would begin a share repurchase for the first time since 2008 to enhance investor returns.